There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Stemline Therapeutics Inc (STML) and Durect Corp (DRRX) with bullish sentiments.
Stemline Therapeutics Inc (STML)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Stemline Therapeutics Inc, with a price target of $38. The company’s shares closed yesterday at $10.53, close to its 52-week low of $10.37.
Selvaraju said:
“Our 12-month price target is derived from a discounted cash flow-based asset value of $1.2B for 15% discount rate and 2% terminal growth rate. Probabilities of success ascribed to SL-401 and SL-701 are 90% and 45%, respectively.”
According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -16.2% and a 18.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Bausch Health Companies Inc, and Aerpio Pharmaceuticals Inc.
Stemline Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $35.50, a 237.1% upside from current levels. In a report issued on November 8, Cowen & Co. also reiterated a Buy rating on the stock.
.
See today’s analyst top recommended stocks >>
Durect Corp (DRRX)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Durect Corp today and set a price target of $3. The company’s shares closed yesterday at $0.83, close to its 52-week low of $0.82.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 9.8% and a 38.2% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Durect Corp with a $3 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
